$RNN Recent News Rexahn prices offering at 30% discount

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$RNN Recent News

Rexahn prices offering at 30% discount 10:58 a.m. Nov. 29, 2012 - MarketWatch.com
AEterna falls; Inspire, Rexahn rally 2:15 p.m. April 16, 2010 - Val Brickates Kennedy
Javelin rockets, Myriad gains on scrapped merger 12:20 p.m. April 12, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 3:26 p.m. April 7, 2010 - MarketWatch
Rexahn, Avanir gain; Sequenom falls 12:32 p.m. April 7, 2010 - Val Brickates Kennedy
Letter up 230% last year without trading 3:00 a.m. Jan. 11, 2010 - Peter Brimelow

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013 7:00 a.m. Jan. 21, 2014 - TheStreet.com
Rexahn Pharmaceutical Shares Are Still A Buy Despite Recent Volatility 3:38 p.m. Jan. 15, 2014 - Seeking Alpha
Rexahn Pharma slides after announcing offering 9:11 a.m. Jan. 15, 2014 - Seeking Alpha
3 Biotechs Getting Plenty Of Attention From Investors 8:26 a.m. Jan. 15, 2014 - Seeking Alpha
Morning Market Losers 9:02 a.m. Jan. 14, 2014 - benzinga.com
Morning Market Movers 8:55 a.m. Jan. 13, 2014 - benzinga.com
Why Rexahn Pharmaceuticals (RNN) Is Up Today 10:35 a.m. Jan. 10, 2014 - TheStreet.com
Rexahn up 15% after Buy rating 1:25 p.m. Jan. 9, 2014 - Seeking Alpha
Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial 12:20 p.m. Jan. 9, 2014 - Seeking Alpha
Rexahn: A Turn Around Story For 2014 12:49 p.m. Dec. 22, 2013 - Seeking Alpha
Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment 1:47 p.m. Nov. 25, 2013 - Seeking Alpha
Rexahn's Recent Clinical Data Points To A New And Better Chemotherapy Pill 7:57 p.m. Oct. 6, 2013 - Seeking Alpha
Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 6:02 a.m. Sept. 30, 2013 - benzinga.com
Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble 4:06 p.m. Sept. 5, 2013 - Seeking Alpha
Teva-Rexahn Deal Terminated - Analyst Blog 10:40 a.m. Aug. 30, 2013 - Zacks.com
10-Q: REXAHN PHARMACEUTICALS, INC. 3:15 p.m. Aug. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors 6:01 a.m. Aug. 7, 2013 - benzinga.com
Rexahn's CEO Uses A Business-Driven Cancer Model For Shareholder Value 5:34 p.m. Aug. 5, 2013 - Seeking Alpha
Rexahn Redesigns Cancer Superdrug Taxotere 12:58 p.m. July 18, 2013 - Seeking Alpha
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform 6:05 a.m. July 17, 2013 - benzinga.com


Opening Buzzers: Chelsea Therapeutics International, Tesla Motors Inc, NQ Mobile Inc, Rexahn Pharmaceuticals 11:02 a.m. Jan. 15, 2014 - ACCESSWIRE
Rexahn Announces $20 Million Registered Direct Offering 8:59 a.m. Jan. 15, 2014 - BusinessWire - BZX
Rexahn Initiates Phase IIa Clinical Trial of Archexin® in Patients with Metastatic Renal Cell Carcinoma 9:00 a.m. Jan. 14, 2014 - BusinessWire - BZX
Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors 8:00 a.m. Jan. 8, 2014 - BusinessWire
Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014 8:00 a.m. Jan. 7, 2014 - BusinessWire
Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin (TM) (RX-5902) 8:17 a.m. Dec. 11, 2013 - BusinessWire
Rexahn Pharmaceuticals to Participate in Brean Capital 2013 Life Sciences Summit 8:00 a.m. Nov. 19, 2013 - BusinessWire
Rexahn Pharmaceuticals Reports Third Quarter Financial Results and Pipeline Update 8:00 a.m. Nov. 14, 2013 - BusinessWire
Rexahn Announces $5.3 Million At Market Registered Direct Offering 8:00 a.m. Oct. 11, 2013 - BusinessWire
Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio State University 7:00 a.m. Oct. 10, 2013 - BusinessWire
Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 7:00 a.m. Sept. 30, 2013 - BusinessWire
Rexahn Awarded Patent in Europe for Cancer Drug Archexin(R) 7:00 a.m. Sept. 12, 2013 - BusinessWire
Rexahn Pharmaceuticals to Present at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9, 2013 7:00 a.m. Sept. 5, 2013 - BusinessWire
Rexahn Pharmaceuticals Provides a Clinical Development and Financial Update 7:00 a.m. Sept. 4, 2013 - BusinessWire
Rexahn Pharmaceuticals Announces Teva will not Exercise its Option to License RX-3117 8:00 a.m. Aug. 28, 2013 - BusinessWire
Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of Supinoxin(TM) (RX-5902) a Candidate for Treating Solid Cancer Tumors 7:00 a.m. Aug. 7, 2013 - BusinessWire
University Of Maryland, Baltimore's Licensing Deals Fuel Local Life Sciences Community 7:30 a.m. Aug. 6, 2013 - PR Newswire
Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering 8:00 a.m. July 24, 2013 - BusinessWire
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform 7:00 a.m. July 17, 2013 - BusinessWire
Rexahn Pharmaceuticals Announce IND Submission for RX-3117 7:00 a.m. July 15, 2013 - BusinessWire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 3

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 6

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 1

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 1

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 3

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 2

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
Machine Grabs Prime Dallas Property Amid Apartment Boom

Updated Category News Views 1

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 3

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Investor Conferences to Watch This Quarter for Growth

Updated Category News Views 256

Introduction to Q1 Investor Conferences This year has begun with a dynamic mix of geopolitical events that have positively impacted domestic energy-sector stocks. As we venture into 2026, the buzz around technological advancements, especially in artificial intelligence, is palpable. Investors are keenly awaiting insights and trends that will be presented at various...

Continue Reading
Triton Digital Unveils U.S. Podcast Rankings for November 2024

Updated Category News Views 191

Overview of the November 2024 Podcast Metrics Triton Digital, a leading provider of technology and services in the digital audio and podcasting sector, has unveiled its reporting period for November 2024, covering from November 4 to December 1. This release comes from Triton’s Podcast Metrics measurement service, which offers critical insights into podcast performances...

Continue Reading
Treasury Bonds Auction Insights: RIKB 26 1015 & RIKB 38 0215

Updated Category News Views 150

Overview of Treasury Bonds Auction Results In a recent auction, two significant treasury bonds were featured: RIKB 26 1015 and RIKB 38 0215. The auction process is a crucial activity in the finance world, presenting opportunities for investors to acquire bonds issued by the government. Each bond serves different funding needs, making it essential to assess their...

Continue Reading
DeepQure's New Clinical Leadership: A Vision for Hypertension Care

Updated Category News Views 162

DeepQure Welcomes New Global Vice President DeepQure, a trailblazer in innovative treatments for hypertension, has made a significant step forward with the recent appointment of Jason G. Jones as the Global Vice President of Clinical & Regulatory Affairs. This strategic move is expected to amplify DeepQure's ambitions as it seeks to redefine hypertension management with...

Continue Reading
Wave Life Sciences Unveils Promising Data for WVE-007 Obesity Therapy

Updated Category News Views 236

Wave Life Sciences Presents Preclinical Findings at ObesityWeek 2025 Wave Life Sciences Ltd. (NASDAQ: WVE), a pioneering biotechnology firm, is excited to share breakthrough preclinical data on WVE-007, an innovative siRNA therapeutic targeting obesity. This research will be spotlighted in a poster presentation at ObesityWeek 2025, which features insights into how WVE-007...

Continue Reading